Cases of osteonecrosis of the jaw (ONJ) have been reported with an increasing frequency over the past few years. ONJ is most often identified in patients with cancer who are receiving intravenous bisphosphonate therapy but it has also been diagnosed in patients receiving oral bisphosphonates for nonmalignant conditions. The condition involves exposed bone of the maxilla or mandible. Although it is often associated with a recent dental surgical procedure, spontaneous ONJ can also occur. Patients commonly present with symptoms. Through case reporting and clinical experience, there is a suggestion that the incidence of ONJ in patients with cancer receiving intravenous bisphosphonates ranges between 1% and 10%. Management of ONJ focuses on maximizing oral health, conservative actions with mouth rinses, antibiotics, and avoidance of unnecessary invasive dental procedures. The currently available data on ONJ are reviewed here.
The bisphosphonates are effetive inhibitors of osteoclast-mediated bone resorption. First developed in the early 1970s, bisphosphonates have provided clinical benefit in the treatment of various benign and malignant bone diseases, including postmenopausal osteoporosis, Paget's disease, and tumor-induced osteolytic lesions. Clinical trials have demonstrated that bisphosphonates significantly reduce the incidence of skeletal complications in patients with multiple myeloma and metastatic disease from breast cancer and other solid tumors.[2,3]
Case reports of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonate therapy have come to attention over the past few years. This condition has also been termed bisphosphonate associated osteo-necrosis and shares some clinical features with neuralgia-inducing cavitational osteonecrosis and osteoradionecrosis. Although the great majority of patients with ONJ were treated with intravenous pamidronate (Aredia) and zoledronic acid (Zometa) for multiple myeloma and metastatic cancer involving the bone, ONJ has also been observed in patients treated with oral alendronate (Fosamax) and risedronate (Actonel) for postmenopausal osteoporosis.[7-10] The pathogenesis of ONJ is undefined and there is no current standard treatment. This article reviews the existing knowledge on ONJ.
Osteonecrosis of the jaw presents as exposed bone in the maxilla and/or mandible. The bone appears necrotic and nonvital. The surrounding mucosa is often inflamed due to secondary infection. Symptoms may range from mild to severe and include pain, drainage, swelling, and anesthesia/paresthesia. Although most case reports note a history of dentoalveolar surgical procedure prior to the development of ONJ (ie, dental extraction, dental implant placement, periodontal surgery, and endodontic surgical procedure), there are reports of patients who have developed ONJ spontaneously[8,11,12] (Figure 1).
The radiographic findings in ONJ are variable. Less advanced ONJ or smaller areas of exposed bone (< 1 cm) is often undetectable on panoramic radiographs but shows faint signals or evidence of bony destruction on bone and CT/MRI scans. Progressive or advanced ONJ shows increased uptake on bone scans and "mottled bone" or areas of lytic changes on CT/MRI scans and panoramic radiographs (Figures 2 and 3).
Histologically, necrotic bone with associated Actinomyces colonization is often seen. Soft tissue or gingival biopsies reveals inflamed squamous mucosa or granulation tissue. The biopsies show no evidence of malignancy (Figure 4).
Cultures reveal normal pharyngeal flora or gram positive cocci, gram negative rods, or polymorphonuclear leukocytes. Actinomyces is often present. The presence of Actinomyces species suggests possible osteomyelitis.
Increasing Number of Reports
Osteonecrosis of the jaw occurring in patients with a history of exposure to bisphosphonates has come to the attention of medical oncologists, dental specialists, and patients through the recent increase in number of case reports in the medical and dental literature over the past 2 to 3 years. Currently, there is no consensus definition or standard staging system for ONJ and there are no pathognomonic clinical, radiographic, or laboratory characteristics. With only a clinical definition for ONJ, the case reports may be influenced by the authors' expert opinions rather than a scientific criteria for diagnosis.
Features common to the recent case reports on ONJ are exposed, necrotic bone in the mandible or maxilla and exposure to bisphosphonates. Osteoradionecrosis shares similar clinical features with ONJ on physical exam. However, ONJ is generally considered to be a separate entity due to the lack of prior radiation exposure. If patients did have jaw exposure to radiation, the dosage would be expected to be less than the 6,000 cGy that is associated with osteoradio-necrosis.[6,13-15]
The established practice of including bisphosphonate administration in the therapy of osseous lesions for multiple myeloma and solid tumors is based on the results of randomized clinical trials demonstrating the efficacy of the bisphosphonates in decreasing the risk of skeletal related events. The American Society of Clinical Oncology has established guidelines for the inclusion of the intravenous bisphosphonates in both breast cancer and multiple myeloma.[17,18] Pamidronate received US Food and Drug Administration (FDA) approval for hypercalcemia of malignancy in 1991, for multiple myeloma in 1995, and for osteolytic metastases from breast cancer in 1996. Zoledronic acid was first approved for hypercalcemia of malignancy in 2001 and in 2002 gained approval for broad use in bone metastases. It is estimated that approximately 1.9 million people have been treated with pamidronate and 1.0 million with zoledronic acid.
In 2002 the FDA received nine spontaneous reports of ONJ in patients with cancer receiving bisphosphonates as part of their care. In 2003 published reports of ONJ began to appear in the literature.[19-22] In response to the observation that patients with ONJ were receiving bisphosphonates, the package inserts for pamidronate and zoledronic acid were updated in 2003 to include information on ONJ in the Precautions and Adverse Reactions sections. Similarly, the prescribing information on the oral bisphosphonates also addresses the potential association between ONJ and bisphosphonate therapy.
In addition to modifying the labeling, Novartis Pharmaceuticals has sent mailings to physicians and dentists specifically addressing oral health for cancer patients on bisphosphonates. These include the "Dear Doctor" letters from September 2004 and May 2005.[23,24] The International Myeloma Foundation similarly has been active in raising awareness of ONJ and has posted information addressing ONJ on their website. With an increasing number of case reports identifying ONJ, particularly in patients treated with zoledronic acid and/or pamidronate, the Oncologic Drugs Advisory Committee addressed concerns regarding ONJ in the March 4, 2005, meeting. At that time the total number of ONJ cases identified through the FDA spontaneous reporting system was 654.
Case reports of ONJ have been presented as abstracts at scientific meetings or published as letters to the editor and manuscripts. Case reports are an important source of information for uncommon events such as ONJ. However, the nature of case reports does not allow for insight into the true incidence of the condition or the lead time to diagnosis. Details on risk factors, comorbid diseases, oral hygiene, and all related therapies are usually not available in reports of ONJ. In addition, information regarding the effects of bisphosphonate "de-challenge" and/or "re-challenge" is limited by the small number of patients within the case series. Case reports are subject to underreporting and reporting bias, and there is no controlling for duplication of reporting. Table 1 highlights ONJ case reports and demonstrates the increase in reporting from 2003 through 2005. The number of case reports continues to expand.
1. Reid IR, King AR, Alexander CJ, et al: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 143-146, 1988.
2. Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97(3 suppl):859-865, 2003.
3. Berenson JR: Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10:52-62, 2005.
4. Migliorati CA, Casiglia J, Epstein J, et al: Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658-1668, 2005.
5. Gruppo R, Glueck CJ, McMahon RE, et al: The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J Lab Clin Med 127:481-488, 1996.
6. Marx RE: Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 41:283-288, 1983
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004.
8. Migliorati CA, Schubert MM, Peterson DE, et al: Bisphosphonate-associated osteonecrosis of the mandibular and maxillary bone. Cancer 104:83-93, 2005.
9. Carter G, Goss AN, Doecke C: Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182:413-415, 2005.
10. Purcell PM, Boyd IW: Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182:417-418, 2005.
11. Estilo CL, Van Poznak C, Williams T, et al: Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study (abstract 8088). Proc Am Soc Clin Oncol 23;747, 2004.
12. Marx RE, Sawatari Y, Fortin M, et al: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosi) of the jaw: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63:1567-1575, 2005.
13. Oh H, Chambers MS, Garden AS, et al: Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. J Oral Maxillofac Surg 62:139-144, 2004.
14. Sulaiman F, Huryn JM, Zlotolow IM: Dental extractions in the irradiated head and neck patient: A retrospective analysis of Memorial Sloan-Kettering Cancer Center protocols, criteria and end results. J Oral Maxillofac Surg 61:1123-1131, 2003.
15. Toljanic JA, Ali M, Haraf DJ, et al: Osteoradionecrosis of the jaws as a risk factor in radiotherapy: A report of an eight-year retrospective review. Oncol Rep 5:345-349, 1998.
16. Coleman RE. Bisphosphonates: Clinical experience. Oncologist 9:14-27, 2004.
17. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042-4057, 2003.
18. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20(17):3719-3736, 2002.
19. ODAC: www.fda.gov/ohrms/dockets/ac/05/questions/2005-4095Q2_02_Zometa-Aredia-Questions.pdf accessed 8-1-06.
20. Wang J, Goodger NM, Pogrel MA: Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104-1107, 2003.
21. Marx RE: Pamidronate (Aredia) and zoledronic acid (Zometa) induced avascular necrosis of the jaw: A growing epidemic. J Oral Maxillofac Surg 61:1115-1118, 2003.
22. Migliorati C: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253, 2003.
23. www.fda.gov/medwatch/SAFETY/2004/ZometaHCP.pdf. Accessed July 18, 2006.
24. www.fda.gov/medwatch/safety/2005/zometa_deardentite_5-5-05.pdf. Accessed July 18, 2006.
25. International Myeloma Foundation: www.myeloma.org. Accessed July 18, 2006.
26. Oncologic Drugs Advisory Committee: www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4095T2.htm. Accessed July 18, 2006.
27. Van Poznak CH, Estilo CL, Sauter NP, et al: Osteonecrosis of the jaw in patients with metastatic breast cancer (abstract 3057). Breast Cancer Res Treat 88(suppl 1):S131, 2004.
28. Hoff AO, Toth B, Altundag K, et al: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Bone Miner Res 20(1):S55:1218, 2005.
29. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99, 2005.
30. Maerevoet M, Martin C, Duck L: Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 353:100-101, 2005.
31. Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587, 2005.
32. Rogers MJ, Gordon S, Benford HL, et al: Cellular and molecular mechanism of action of bisphosphonates. Cancer 88:2961-2978, 2000.
33. Odvina CV, Zewekh JE, Rao S, et al: Serverely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301, 2005.
34. Woo S-B, Hande K, Richardson PG: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:100, 2005.
35. Komatsubara S, Mori S, Mashiba T, et al: Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005, 2004.
36. Mashiba T, Hirano T, Turner CH, et al: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613-620, 2000.
37. Komatsubara S, Mori S, Mashiba T, et al: Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18(3):512-520, 2003.
38. Lugassy G, Shaham R, Nemets A, et al: Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. Am J Med 117:440-441, 2004.
39. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonate inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954, 2000.
40. Croucher PI, De Raeve H, Perry MJ, et al: Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis and increased survival. J Bone Miner Res 18:482-492, 2003.
41. Fournier P, Boissier S, Filleur S, et al: Bisphosphonate inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in ventral prostate in castrated rats. Cancer Res 62:6538-6544, 2002.
42. Wood J, Bonjean K, Ruetz S, et al: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exper Ther 302:1055-1061, 2002.
43. Liu Y-F, Chen W-M, Lin Y-F, et al: Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med 352:2294-2301, 2005.
44. Assouline-Dayan Y, Chang C, Greenspan A, et al: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94-124, 2002.
45. Talamo G, Antuaco E, Walker R, et al: Avascular necrosis of femoral and/or humeral heads in multiple myeloma: Results from a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 23:5217-5223, 2005.
46. Taking Care of Yourself While Living With Cancer: Dental Health and Osteonecrosis of the Jaw. http://myeloma.org/pdfs/PatientDentalBrochure.pdf Accessed July 18, 2006.
47. Ruggiero S: The American Association of Oral and Maxillofacial Surgeons, 87th Annual Meeting. Mini-Symposium on New Concepts on Bone Necrosis. Boston, September 23, 2005.
48. Morris CD, Einhorn TA: Bisphosphonates in orthopedic surgery. J Bone Joint Surg 87:1609-1618, 2005.
49. Fleisch H: Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16(3):437-440, 2001.
50. Coleman RE: Skeletal complications of malignancy. Cancer 80(8 suppl):1588-1594, 1997.
51. Little DG, Peat R, McEvoy A, et al: Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wister rats. J Bone Miner Res 18:2016-2022, 2003.
52. Agarwala S, Jain D, Joshi VR, et al: Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology 44(3):352-359, 2005.
53. Lai, K-A, Shen, W-J, Yang, C-Y, et al: The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg 87:2155-2159, 2005.
55. Melo MD, Obeid G: Osteonecrosis of the jaw in patients with a history of receiving bisphosphonate therapy. Strategies for prevention and early recognition. J Am Dent Assoc 136:1675-1681, 2005.
56. Markiewics MR, Margone JE, Campbell JH, et al: Bisphosphonate associated osteonecrosis of the jaw. A review of current knowledge. J Am Dent Assoc 136:1669-1674, 2005.
57. Bagan JV, Murillo J, Jiménez Y, et al: Avascular jaw oseonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med 34:120-123, 2005.
58. Sanna G, Zampino MG, Pelosi G, et al: Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 16:1207-1208, 2005.
59. Vannucchi AM, Ficarra G, Antonioli E, et al: Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 128:738-738, 2005.
60. Ficarra G, Beninati F, Rubino I: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32:1123-1128, 2005.
61. Lenz J-H, Steiner-Krammer B, Schmidt W, et al: Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 33:395-403, 2005.
62. Katz H: Endodontic Implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases. J Endodontics 31:831-834, 2005.
63. Sarathy A, Bourgeois SL, Goodell GG, et al: Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: Two case reports. J Endodontics 31(10):759-763, 2005.
64. Kut V, Mehta J, Tariman J, et al: Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood 104:4933, 2004.
65. Schuster MW, Dymek JM: Oral cavity avascular bone necrosis-A newly recognized complication of intravenous (IV) bisphosphonate therapy in cancer patients. Blood 104:4905, 2004.
66. Thakkar SG, Isada C, Englund K, et al: Bisphosphonate therapy associated with an increased incidence of mandibular/maxillary osteomyelitis in multiple myeloma patients. Blood 104:4925, 2004.
67. Zarychanski R, Elphee E, Embil J, et al: Osteonecrosis of the jaw associated with pamidronate therapy. Blood 104:4908, 2004.
68. Migliorati C: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253, 2003.
69. National Institutes of Health: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional. Accessed July 18, 2006.
70. Zoledronic acid prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf. Accessed: July 18, 2006.
71. Pamidronate prescribing information. http://www.fda.gov/medwatch/SAFETY/2005/Feb_PI/Aredia_PI.pdf. Accessed July 18, 2006.